Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth

By Vandana Singh

Exact Sciences Corp (NASDAQ: EXAS ) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the consensus of $599.03 million .

Screening revenue was $462.8 million, an increase of 31%. Precision Oncology

You are viewing a robot-friendly page.Click hereto reload in standard format.